Cardio-oncology is the cardiac care of cancer patients. Cardiac issues may develop during cancer treatment or may be pre-existing or may develop as late effects. There has been increasing recognition of these issues recently which has led to the development of the new sub-speciality of cardio-oncology bringing together cardiologists, oncologists and allied healthcare professionals.

This Cardio-oncology section showcases key papers in the field to allow readers to quickly familiarise themselves with the latest advances in this rapidly developing field. There will be work related to the different cardiac complications of cancer treatment e.g. acute coronary syndromes, myocarditis, heart failure and arrhythmias. Research focussing on specific cancer therapies and their cardiotoxicities will also be featured e.g. immunotherapies, targeted therapies, cytotoxic drugs, radiotherapy etc. Finally this section will enable the reader to reference the most up-to-date guidelines in the field from national and international organisations.

Close X
Other videos you might like
Dr Arjun K Ghosh

Section Advisor

Dr Arjun K Ghosh

Consultant Cardiologist, Barts Heart Centre, University College London Hospital and Hatter Cardiovascular Institute, UK

The Radcliffe cardio-oncology educational hub is an independent program led by Dr Arjun K Ghosh.

Recent Videos


Cardio-oncology A-Z: Late Effects Cardiotoxicity

Neha Bansal,

Watch time: 8m 22s


Cardiac Issues in Prostate Cancer

Arjun K Ghosh, Darryl Leong, Mark Linch, et al


CV Impact of Immune Checkpoint Inhibitor Cardiotoxicity

Arjun K Ghosh, Tomas Neilan,

Watch time: 28m 3s


How to Set up a Cardio-Oncology Service

Daniel Lenihan, Arjun K Ghosh,


What to Do When the Systolic Function Falls During Breast Cancer Treatment

Arjun K Ghosh, Rebecca Dobson, Elisavet Papadimitraki , et al

Watch time: 31m 14s


Cardio-oncology Discussion: Primary PCI in Cancer Patients

Arjun K Ghosh, Deepak L Bhatt, Cezar Iliescu, et al

Watch time: 36m 6s
A Systematic Review and Meta-Analysis of Beta-Blockers and Renin-Angiotensin System Inhibitors for Preventing Left Ventricular Dysfunction Due to Anthracyclines or Trastuzumab in Patients With Breast Cancer

Lewinter C et al. Eur Heart J. 2022;43(27):2562-2569.

How to Treat Breast Cancer After Childhood Cancer: Management of Oncologic and Cardiovascular Concerns

Blaes AH et al. JACC CardioOncol. 2022;4(1):126-129.

Validity of Estimated Cardiorespiratory Fitness in Patients With Primary Breast Cancer

Michalski M et al. JACC CardioOncol. 2022;4(2):210-219.

Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors: A Cross-Sectional Study

Naaktgeboren WR et al. JACC CardioOncol. 2022;4(2):183-191.

Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study

Greenlee H et al. J Clin Oncol. 2022;40(15):1647-1658.

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol

Heck S, et al. Circulation 2021;143:2431–2440.

Risk, Nature of Cardiac Toxicity in Breast Cancer Is Variable

Jiminez, R, AJMC, Risk, Nature of Cardiac Toxicity in Breast Cancer Is Variable, 2020. [Accessed: 6 Sep 2022.]

Summary of Clinical Trials for the Prevention and Treatment of Cardiomyopathy Related to Anthracyclines and HER2-Targeted Agents

Tuzovic, M, Yang, E, Witteles, R. ACC 2020. [Accessed: 6 Sep 2022].

Emerging cardio-oncology field targets breast cancer patients' risk for heart disease

Narula, T. Youtube, 2019. [Accessed: 6 September 2022.]

Cardio-oncology field fights heart disease in breast cancer patients

Narula, T, Youtube, 2019. [Accessed: 6 September 2022.]

No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery: 20-Year Follow-up of the Randomized SweBCGRT Trial

Killander F et al. Int J Radiat Oncol Biol Phys. 2020;107(4):701-709.

Comprehensive Assessment of Changes in Left Ventricular Diastolic Function With Contemporary Breast Cancer Therapy

Upshaw JN et al. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):198-210.

Male Breast Cancer Patients Face High Prevalence of CV Disease Risk Factors

ACC News Story. Jan 25, 2021

Cardiovascular disease amongst women treated for breast cancer: traditional cytotoxic chemotherapy, targeted therapy and radiation therapy

Current Cardiology Reports 2021; 23:16.

Comparative Efficacy and Safety of Trastuzumab Biosimilars to the Reference Drug: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Cargnin S et al. Cancer Chemother Pharmacol. 2020;86(5):577-588.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

Piccart M et al. J Clin Oncol. 2021;13:1448-1457.

Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study

Abdel-Qadir, H et al. J Am Heart Assoc. 2021;10(2):e018393.

Six Months vs. 12 Months of Adjuvant Trastuzumab Among Women With HER2-Positive Early-Stage Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Deng H et al. Front Oncol. 2020;10:288.

Long-Term Follow-up Assessment of Cardiac Safety in SAFE-HEaRt, a Clinical Trial Evaluating the Use of HER2-Targeted Therapies in Patients With Breast Cancer and Compromised Heart Function

Khoury, K et al. Breast Cancer Res Treat. 2021;185:863–868.

A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer

Ben Kridis, W et al. Am J Clin Oncol. 2020;43(7):510-516.

Association of Early-Stage Breast Cancer and Subsequent Chemotherapy With Risk of Atrial Fibrillation

Abdel-Qadir, H et al. JAMA Netw Open. 2019;2(9):e1911838.

Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial

Leong, DP et al. JACC: CardioOncology 2019; 1(1):1-10.

An Evaluation of the Safety of Continuing Trastuzumab Despite Overt Left Ventricular Dysfunction

Barron, CC et al. Curr Oncol. 2019;26(4):240-246.

The Risk of Heart Failure and Other Cardiovascular Hospitalizations After Early Stage Breast Cancer: A Matched Cohort Study

Abdel-Qadir, H et al. J Natl Cancer Inst. 2019;111(8):854-862.

Real-Time Exercise Reduces Impaired Cardiac Function in Breast Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial

Chung WP et al. Ann Phys Rehabil Med. 2021:101485.

Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Results From a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study

Swain SM et al. Lancet Oncol. 2020;21(4):519-530.

Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study

Kolberg HC et al. Drug Saf. 2020;43(3):233-242.

Anthracycline-Induced Cardiotoxicity Prevention With Angiotensin-Converting Enzyme Inhibitor Ramipril in Women With Low-Risk Breast Cancer: Results of a Prospective Randomized Study

Słowik A et al. Kardiol Pol. 2020;78(2):131-137.

6 Months Versus 12 Months of Adjuvant Trastuzumab in Early Breast Cancer (PHARE): Final Analysis of a Multicentre, Open-Label, Phase 3 Randomised Trial

Pivot, X et al. Lancet. 2019;393(10191):2591-2598.

6 Versus 12 Months of Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer (PERSEPHONE): 4-Year Disease-Free Survival Results of a Randomised Phase 3 Non-Inferiority Trial

Earl HM et al. Lancet. 2019;393(10191):2599-2612.

Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer

Guglin M et al. J Am Coll Cardiol. 2019;73(22):2859-2868.

Prospective Evaluation of the Cardiac Safety of HER2-Targeted Therapies in Patients With HER2-Positive Breast Cancer and Compromised Heart Function: The SAFE-HEaRt Study

Lynce, F et al. Breast Cancer Res Treat. 2019;175(3):595-603.

Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial

Nabati M et al. J Cardiovasc Pharmacol Ther. 2019;24(3):233-241.

Does Prostate-Cancer Treatment Place a Strain on the Heart?

Schmidt C et al. Nature. 2022;609(7927):S46-S47.

Clinical Practice Guidelines in Cardio-Oncology

Leong DP et al. Heart Fail Clin. 2022;18(3):489-501.

International Consensus Statement on the Management of Cardiovascular Risk of Bruton's Tyrosine Kinase Inhibitors in CLL

Awan FT et al. Blood Adv. 2022;bloodadvances.2022007938.

Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association

Beavers CJ et al. Circulation. 2022;145(15):e811-e838.

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Lyon AR et al. Eur Heart J. 2022:ehac244.

Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update

Giordano SH et al. J Clin Oncol. 2022;40(23):2612-2635.

Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society

Mitchell JD, et al. JACC CardioOncol 2021;3(3):360-380.

Effect of Primary Percutaneous Coronary Intervention on In-Hospital Outcomes Among Active Cancer Patients Presenting With ST-Elevation Myocardial Infarction: a Propensity Score Matching Analysis

Mohamed MO et al. Eur J Acute Cardiovasc Care 2021.

Cardio-Oncology: Recommendations From the Guidelines

Houston Methodist DeBakey CV Education, 2019. (accessed 22 November 2022).

Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer

Ehrhardt, MJ et al. J Clin Oncol. 2020;38(33):3851-3862.

Adherence to Surveillance for Second Malignant Neoplasms and Cardiac Dysfunction in Childhood Cancer Survivors: A Childhood Cancer Survivor Study

Yan, AP et al. J Clin Oncol. 2020;38(15):1711-1722.

Major Cardiac Events for Adult Survivors of Childhood Cancer Diagnosed Between 1970 and 1999: Report From the Childhood Cancer Survivor Study Cohort

Mulrooney, DA et al. BMJ. 2020;368:l6794.

British Society of Echocardiography and British Cardio-Oncology Society Cardio-Oncology guidelines JACC Cardio-Oncology and Echo Research and Practice (joint publication) 2021 (in press)

Dobson R, et al. Echo Research and Practice 2021; 8(1): G1-G18.

Common Mechanistic Pathways in Cancer and Heart Failure. A Scientific Roadmap on Behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

de Boer, RA et al. Eur J Heart Fail. 2020;22(12):2272-2289.

Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement From the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology

Pudil, R et al. Eur J Heart Fail. 2020;22(11):1966-1983.

Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association

Tisdale, JE et al. Circulation. 2020;142(15):e214-e233.

Management of Cardiac Disease in Cancer Patients Throughout Oncological Treatment: ESMO Consensus Recommendations

Curigliano, G et al. Ann Oncol. 2020;31(2):171-190.

Correction to: Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association

Circulation. 2019;140(9):e543.

Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association

Gilchrist, SC et al. Circulation. 2019;139(21):e997-e1012.

Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association

Campia, U et al. Circulation. 2019;139(13):e579-e602.

Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology State-of-the-Art Review

Glen C et al. JACC CardioOncol. 2022;4(1):1-18.

The Role of Cardioprotection in Cancer Therapy Cardiotoxicity: JACC: CardioOncology State-of-the-Art Review

Omland T et al. JACC CardioOncol. 2022;4(1):19-37.

Immune-Checkpoint Inhibitors: Long-Term Implications of Toxicity

Johnson DB et al. Nat Rev Clin Oncol. 2022;19(4):254-267.

An Integrated Approach to Cardioprotection in Lymphomas

Maraldo MV et al. Lancet Haematol. 2022;9(6):e445-e454.

Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions

Interventional Cardiology Review 2019;14(2):89–94.

Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology

Cardiac Failure Review 2019;5(2):106–11.

Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients

Cardiac Failure Review 2019;5(2):112–8.

Clinical Features and Outcomes of Patients with Chemotherapy-induced Takotsubo Syndrome

US Cardiology Review 2019;13(2):74–82.

Subclinical Left Ventricular Dysfunction During Chemotherapy

Cardiac Failure Review 2019;5(1):31–6.

The Future Role of Cardio-oncologists

Cardiac Failure Review 2017;3(2):140–2.

Cancer and Heart Failure: Understanding the Intersection

Cardiac Failure Review 2017;3(1):66–70.

Cardiac Toxicity of Cancer Chemotherapy

US Cardiology Review 2017;11(1):20–4

From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach

Minotti G et al. JACC CardioOncol. 2022;4(1):139-140.

How to Apply Translational Models to Probe Mechanisms of Cardiotoxicity

Livingston CE et al. JACC CardioOncol. 2022;4(1):130-135.

Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay

Schirone L et al. Cells. 2022;11(13):2000.

Cardiac Remodeling in Cancer-Induced Cachexia: Functional, Structural, and Metabolic Contributors

Wiggs MP et al. Cells. 2022;11(12):1931.

A Systematic Review of miRNAs As Biomarkers for Chemotherapy-Induced Cardiotoxicity in Breast Cancer Patients Reveals Potentially Clinically Informative Panels As Well as Key Challenges in miRNA Research

Brown C et al. Cardiooncology. 2022;8(1):16.

Immune Checkpoint Inhibitor Therapy Aggravates T Cell-Driven Plaque Inflammation in Atherosclerosis

Poels L, et al. JACC CardioOncol 2020;2(4):599-610.

A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention

Wei SC, et al. Cancer Discov 2021;11(3):614-625.

Hypertensive Cardiotoxicity in Cancer Treatment—Systematic Analysis of Adjunct, Conventional Chemotherapy, and Novel Therapies—Epidemiology, Incidence, and Pathophysiology

Chung R et al. Journal of Clinical Medicine 2020;9(10):3346.

Cardiac Dysfunction in Cancer Patients: Beyond Direct Cardiomyocyte Damage of Anticancer Drugs: Novel Cardio-Oncology Insights From the Joint 2019 Meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart

Tocchetti CG et al. Cardiovasc Res. 2020;116(11):1820-1834.

Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy

Wallace KB et al. Circ Res. 2020;126(7):926-941.

Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque

Drobni, ZD et al. Circulation. 2020;142(24):2299-2311.

Cardio-Oncology: Low-Grade Inflammation as a Common Pathway of Cancer and Cardiovascular Disease

Lüscher TF et al. Eur Heart J. 2019;40(48):3871-3874.

Implementation of Cardio-Oncology Training for Cardiology Fellows

Tuzovic M, et al, J Am Coll Cardiol CardioOnc. 2020;2(5):795–799.

Cardio-Oncology Education and Training: JACC Council Perspectives

Alvarez-Cardona JA et al. J Am Coll Cardiol. 2020;76(19):2267-2281.

Cardio-Oncology: Twitter Chat as a Mechanism for Increasing Awareness of Heart Health for Cancer Patients

Conley, CC et al. Cardiooncology. 2020;6(19).

An International Survey of Healthcare Providers’ Knowledge of Cardiac Complications of Cancer Treatments

Peng, J et al. Cardiooncology. 2019;5(12).

Cardiovascular Disease Risk Among Cancer Survivors: The Atherosclerosis Risk In Communities (ARIC) Study

Florido R et al. J Am Coll Cardiol. 2022;80(1):22-32.

Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma Treated With Targeted Therapies

Chen DY et al. JACC CardioOncol. 2022;4(2):223-234.

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute-Cancer Therapy Evaluation Program

Naqash AR et al. J Clin Oncol. 2022;JCO2200369.

Research Quality and Impact of Cardiac Rehabilitation in Cancer Survivors: A Systematic Review and Meta-Analysis

Fakhraei R et al. JACC CardioOncol. 2022;4(2):195-206.

Cardiovascular Adverse Events in Oncology Trials: Understanding and Appreciating the Differences Between Clinical Trial Data and Real-World Reports

Ewer MS et al. Cardiooncology. 2022;8(1):13.

Cardio-Onco-Metabolism: Metabolic Remodelling in Cardiovascular Disease and Cancer

Karlstaedt A et al. Nat Rev Cardiol. 2022;19(6):414-425.

Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database

Alexandre J, et al. Eur Heart J Cardiovasc Pharmacother 2021;7(4):312-320.

Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis

Awadalla M, et al. J Am Coll Cardiol 2020;75:467-478.

Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects

Jennifer M Yeh, Anju Nohria, Lisa Diller, et al. Ann Intern Med. 2014;160(10):661-71.

Racial and Ethnic Disparities in Cardio-Oncology: A Call to Action

Fazal M, et al, J Am Coll Cardiol CardioOnc, 2021;3(2):201–204

Risk of Atrial Fibrillation According to Cancer Type: A Nationwide Population-Based Study

Yun J et al. J Am Coll Cardiol CardioOnc. 2021; 3(2), 221–232.

Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review

Rao VU et al. J Am Coll Cardiol 2021;77(21):2693-2716.

HFpEF After Cancer Therapy

Upshaw, J, ACC, 2020. [Accessed: 6 Sept 2022.]

Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis and ACS

Turker, I, Jahangir, E, ACC, 2020. [Accessed: 6 September 2022.]

Acute CV Complications of Hematopoietic Stem Cell Transplantation

Ryan, T, Rotz, S, Hayek, S, ACC, 2021. [Accessed: 6 September 2022.]

Cardiotoxicity from chemotherapy (cardio-oncology) An echocardiography case and discussion

Chatziathanasiou, G, Youtube, 2019. [Accessed: 6 September 2022.]

Cardio-oncology: What is it? + FAQs

Ray, J, Advani, P, Mayo Clinic, Youtube, 2020. [Accessed: 6 September 2022.]

Echo Assessment of LV Function: EF, Strain, Cardio-oncology

Quiñones, M, Youtube, 2019. [Accessed: 6 September 2022.]

Cardio-Oncology in 2019

Sahni, G, Youtube, 2019. [Accessed: 6 September 2022.]

Heart Age Among Cancer Survivors

Scott LC, Yang Q, Dowling NF, Richardson LC. MMWR 2021;70:1–6.

Pericardial Disease in Cancer Patients

Ghosh AK et al. Current Treatment Options in Cardiovascular Medicine 2018,20(7):60.

Cardiac Computed Tomography in Cardio-Oncology: An Update on Recent Clinical Applications

Rominin S et al. EHJ Cardiovascular Imaging 2021;22(4):397–405.

Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer

Atkins KM et al. JAMA Oncol. 2021;7(2):206-219.

Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the Eur

Čelutkienė J et al. Eur J Heart Fail. 2020;22(9):1504-1524.

Cardiotoxicity and Myocardial Hypoperfusion Associated With Anti-Vascular Endothelial Growth Factor Therapies: Prospective Cardiac Magnetic Resonance Imaging in Patients With Cancer

Dobbin SJH et al. Eur J Heart Fail. 2020;22(7):1276-1277.

Longitudinal Changes in Echocardiographic Parameters of Cardiac Function in Pediatric Cancer Survivors

Border WL et al. JACC CardioOncol. 2020;2(1):26-37.

Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation

Witt JS et al. Am J Clin Oncol. 2019;42(8):662-667.

Statin Use and Risk of Vascular Events Among Cancer Patients After Radiotherapy to the Thorax, Head, and Neck

Boulet J et al. J Am Heart Assoc. 2019;8(13):e005996.

Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer

Atkins KM et al. J Am Coll Cardiol. 2019 Jun 18;73(23):2976-2987.

ACCEL Lite: Primary PCI in Patients With Active Cancer Presenting With STEMI

Bailey, A, Barac, A, Kim, S, Mamas, M, ACC, 2021. [Accessed: 6 September 2022.]

Cardio-oncology and the future of heart failure

Lüscher, T, Eur Heart J, 2020; 18:1709-1712.

Cardiac Tumors: JACC CardioOncology State-of-the-Art Review

Tyebally S…. Ghosh AK et al. JACC Cardio-Oncology 2020;2:293-311.

Socio-Economic Burden of Myocardial Infarction Among Cancer Patients

Guha A et al. American Journal of Cardiology 2020;S0002-9149(20)31229-7.

Cardiovascular Complications of Prostate Cancer Therapy

Campbell C…. Ghosh AK. et al. Current Treatment Options in Cardiovascular Medicine 2020;22:69.

Cardiotoxicity: Precision Medicine With Imprecise Definitions

Chung R et al. Open Heart 2018;5(2):e000774.

Effects of Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Use on Cancer Therapy-Related Cardiac Dysfunction: A Meta-Analysis of Randomized Controlled Trials

Fang K et al. Heart Fail Rev. 2021;26(1):101-109.

Review of Late CV Effects After Hematopoietic Stem Cell Transplantation

Ryan TD et al. ACC Expert Analysis, Jan 25, 2021.

Management of Immune Checkpoint Inhibitor–Induced Myocarditis: The French Working Group’s Plea for a Pragmatic Approach

Thuny F et al. J Am Coll Cardiol CardioOnc 2021;3(1):157-161.

The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer

Zhang L et al. J Am Coll Cardiol CardioOnc 2021:3(1);35-47.

Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia

Herrmann J et al. Nat Rev Cardiol. 2020;17(8):474-502.

Outcomes of Cardiac Resynchronization Therapy in Patients with Chemotherapy-Induced Cardiomyopathy

Ezzeddine, FM et al. Pacing Clin Electrophysiol. 2021;44(4):625-632.

Adverse Cardiac Events in the Treatment of Non-Small Cell Lung Cancer With Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: A Protocol for Systematic Review and Meta-Analysis

Li H et al. Medicine (Baltimore). 2020;99(32):e21613.

Challenges and Solutions in Management of Cardiotoxicity Induced by Checkpoint Inhibitors

Beáta M et al. Klin Onkol. 2020;33(5):350-355.

Role of Cardioprotective Agents on Chemotherapy-Induced Heart Failure: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Li X et al. Pharmacol Res. 2020;151:104577.

Long-Term Cardiovascular Disease Mortality Among 160 834 5-Year Survivors of Adolescent and Young Adult cancer: an American Population-Based Cohort Study

Wang, L et al. Eur Heart J. 2021;42(1):101-109.

Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease

Aboumsallem JP et al. J Am Heart Assoc. 2020;9(2):e013754.

Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week

Ball S et al. J Am Coll Cardiol. 2019;74(13):1714-1727.

Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis

Oikonomou EK et al. JAMA Cardiol. 2019;4(10):1007-1018.

The Risk of Cardiac Events in Patients Receiving Immune Checkpoint Inhibitors: a Nationwide Danish Study

D'Souza M et al. Eur Heart J. 2020;42(16):1621–1631.

Intensified Immunosuppressive Therapy in Patients With Immune Checkpoint Inhibitor-Induced Myocarditis

Cautela, J et al. J Immunother Cancer. 2020;2:e001887.

Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy

Vaduganathan M et al. JACC CardioOncol. 2019;1(1):54-65.

Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week

Libby P et al. J Am Coll Cardiol. 2019;74(4):567-577.

Increased Resting Heart Rate and Prognosis in Treatment-Naïve Unselected Cancer Patients: Results From a Prospective Observational Study

Anker, MS et al. Eur J Heart Fail. 2020;22(7):1230-1238.

Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology

Bonaca MP et al. Circulation. 2019;140(2):80-91.

Bidirectional Relationship Between Cancer and Heart Failure: Old and New Issues in Cardio-oncology

Bertero E et al. Card Fail Rev. 2019;5(2):106-111.

Long-Term Outcomes of Primary Cardiac Malignancies: Multi-Institutional Results From the National Cancer Database

Sultan, I et al. J Am Coll Cardiol. 2020;75(18):2338-2347.

Classification, Prevalence, and Outcomes of Anticancer Therapy-Induced Cardiotoxicity: the CARDIOTOX Registry

López-Sendón, J et al. Eur Heart J. 2020;41(18):1720-1729.

Common Risk Factors for Heart Failure and Cancer

Meijers WC et al. Cardiovasc Res. 2019;115(5):844-853.

Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy

Singh, JP et al. JAMA. 2019;322(18):1799-1805.

The Landscape of Cardiovascular Care in Pediatric Cancer Patients and Survivors: A Survey by the ACC Pediatric Cardio-Oncology Work Group

Ryan, TD et al. Cardiooncology. 2019;5(16).

Trends in Modes of Death in Heart Failure Over the Last Two Decades: Less Sudden Death but Cancer Deaths on the Rise

Moliner, P et al. Eur J Heart Fail. 2019;21(10):1259-1266.

Medium and Long-Term Risks of Specific Cardiovascular Diseases in Survivors of 20 Adult Cancers: A Population-Based Cohort Study Using Multiple Linked UK Electronic Health Records Databases

Strongman, H et al. Lancet. 2019;394(10203):1041-1054.

Cancer Treatment and Survivorship Statistics, 2019

Miller, KD et al. CA Cancer J Clin. 2019;69(5):363-385.

Transdermal Oestradiol for Androgen Suppression in Prostate Cancer: Long-Term Cardiovascular Outcomes From the Randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) Trial Programme

Langley RE et al. Lancet. 2021;397(10274):581-591.

Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy

Thavendiranathan P et al. J Am Coll Cardiol. 2021;77(4):392-401.

Takotsubo Syndrome in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A New Adverse Cardiac Complication

Ederhy, S et al. Eur J Heart Fail. 2019;21(7):945-947.

Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 1 Year Results of the SUCCOUR Trial

T Negishi et al. European Heart Journal. 2020;41(2): ehaa946.3282.

Increasing Evidence for and a Word of Caution About an Association Between Cancer and Congenital Heart Disease

Gurvitz, M et al. JAMA Netw Open. 2019;2(7):e196756.

Risk of Cancer Among Children and Young Adults With Congenital Heart Disease Compared With Healthy Controls

Mandalenakis, Z et al. JAMA Netw Open. 2019;2(7):e196762.

Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer

Ehrhardt, MJ et al. J Clin Oncol. 2020;38(33):3851-3862.

Therapy-Related Cardiac Risk in Childhood Cancer Survivors: An Analysis of the Childhood Cancer Survivor Study

Bates, JE et al. J Clin Oncol. 2019;37(13):1090-1101.

Paediatric Cardio-Oncology: Epidemiology, Screening, Prevention, and Treatment

Chow, EJ et al. Cardiovasc Res. 2019;115(5):922-934.

Upfront Dexrazoxane for the Reduction of Anthracycline-Induced Cardiotoxicity in Adults With Preexisting Cardiomyopathy and Cancer: A Consecutive Case Series

Ganatra, S et al. Cardiooncology. 2019;5(1).

Can I climb a mountain? Tips and tricks for patients at heart failure congress

Antipolis S, Radcliffe Cardiology 2018

Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues

Arrhythmia & Electrophysiology Review 2023;12:e16.

Cancer and Postradiotherapy Cardiotoxicity: How to Face Damage in Women’s Hearts?

European Cardiology Review 2023;18:e08.

Cardio-oncology in 2022

European Cardiology Review 2023;18:e04.

Chest Pain in the Cancer Patient

European Cardiology Review 2022;17:e15.

Chrysanthemum morifolium Extract Prevents the Development of Doxorubicin-induced Heart Failure

European Cardiology Review 2021;16:e65.

Mechanisms of Cardiotoxicity Associated with Tyrosine Kinase Inhibitors in H9c2 Cells and Mice

European Cardiology Review 2020;15:e33.

AF in Cancer Patients: A Different Need for Anticoagulation?

European Cardiology Review 2019;14(1):65–7

Guest Editorial: Is Cardio-oncology Ready for Algorithms?

European Cardiology Review 2018;13(1):62–3.

Cardio-oncology: A Focus on Cardiotoxicity

European Cardiology Review 2018;13(1):64–9.